Unicycive Therapeutics, Inc.UNCYNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -165.42% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -750.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +172.56% | +92.73% | +234.60% | +224.47% | +103.11% |
| Weighted Average Shares Diluted Growth | +172.56% | +92.73% | +254.70% | +30.80% | +103.11% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +98.41% | +123.16% | -46.65% | -32.90% | +31.20% |
| Book Value per Share Growth | +197.56% | +0.00% | -84.50% | -83.84% | -33.74% |
| Debt Growth | -6.81% | -4.69% | -2.94% | -24.92% | -37.42% |
| R&D Expense Growth | -9.70% | +24.92% | -68.13% | -64.05% | -2.66% |
| SG&A Expenses Growth | +24.94% | +91.01% | +176.13% | +105.80% | +36.56% |